A second-line degrader battle beckons
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
Hutchmed starts phase 1 with a project in a field where Syndax and Kura have so far been the main players.
Maplirpacept features among key biologicals and small molecules highlighted at Pfizer’s oncology update.
Arvinas’s SERD appears to edge out Olema’s, but what’s the best CDK4/6 inhibitor for a phase 3 combination?
Palazestrant joins vepdegestrant in pivotal development, as SERDs continue their rollercoaster ride.